Dr. Paul B. Chapman on Optimizing Targeted Therapy in Melanoma
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.
Cancer Network spoke with Paul B. Chapman, MD, medical oncologist at Memorial Sloan-Kettering Cancer Center, about current strategies and research surrounding optimized targeted therapy in melanoma. This was the topic of an educational session Chapman presented at ASCO 2019.
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
